JP2005502319A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502319A5
JP2005502319A5 JP2002579898A JP2002579898A JP2005502319A5 JP 2005502319 A5 JP2005502319 A5 JP 2005502319A5 JP 2002579898 A JP2002579898 A JP 2002579898A JP 2002579898 A JP2002579898 A JP 2002579898A JP 2005502319 A5 JP2005502319 A5 JP 2005502319A5
Authority
JP
Japan
Prior art keywords
antibody
polypeptide
dna
fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002579898A
Other languages
English (en)
Japanese (ja)
Other versions
JP4370428B2 (ja
JP2005502319A (ja
Filing date
Publication date
Priority claimed from FR0104712A external-priority patent/FR2823221B1/fr
Application filed filed Critical
Publication of JP2005502319A publication Critical patent/JP2005502319A/ja
Publication of JP2005502319A5 publication Critical patent/JP2005502319A5/ja
Application granted granted Critical
Publication of JP4370428B2 publication Critical patent/JP4370428B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

JP2002579898A 2001-04-06 2002-04-05 疾患関連タンパク質 Expired - Lifetime JP4370428B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104712A FR2823221B1 (fr) 2001-04-06 2001-04-06 Sequences associees a la degenerescence retinienne et applications
PCT/EP2002/003810 WO2002081513A2 (en) 2001-04-06 2002-04-05 Disease-associated protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009050689A Division JP4571695B2 (ja) 2001-04-06 2009-03-04 疾患関連タンパク質

Publications (3)

Publication Number Publication Date
JP2005502319A JP2005502319A (ja) 2005-01-27
JP2005502319A5 true JP2005502319A5 (enExample) 2009-06-18
JP4370428B2 JP4370428B2 (ja) 2009-11-25

Family

ID=8862037

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002579898A Expired - Lifetime JP4370428B2 (ja) 2001-04-06 2002-04-05 疾患関連タンパク質
JP2009050689A Expired - Lifetime JP4571695B2 (ja) 2001-04-06 2009-03-04 疾患関連タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009050689A Expired - Lifetime JP4571695B2 (ja) 2001-04-06 2009-03-04 疾患関連タンパク質

Country Status (22)

Country Link
US (6) US7795387B2 (enExample)
EP (1) EP1379657B1 (enExample)
JP (2) JP4370428B2 (enExample)
KR (1) KR100913258B1 (enExample)
CN (1) CN1529753B (enExample)
AU (1) AU2002312794B8 (enExample)
BR (1) BRPI0208870B8 (enExample)
CA (1) CA2443345C (enExample)
CZ (1) CZ305800B6 (enExample)
EC (1) ECSP024345A (enExample)
ES (1) ES2597835T3 (enExample)
FR (1) FR2823221B1 (enExample)
HU (1) HU226307B1 (enExample)
IL (3) IL158013A0 (enExample)
MX (1) MXPA03009114A (enExample)
NO (1) NO331277B1 (enExample)
NZ (1) NZ528376A (enExample)
PL (1) PL213658B1 (enExample)
RU (1) RU2384586C2 (enExample)
SK (1) SK288465B6 (enExample)
WO (1) WO2002081513A2 (enExample)
ZA (1) ZA200307403B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US7261544B2 (en) 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
FR2870241B1 (fr) * 2004-05-13 2015-02-27 Novartis Ag Facteur de viabilite des cones derive des batonnets ou rdcvf et applications
EP2027889A1 (en) * 2007-06-05 2009-02-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) New neuronal viability factor and use thereof
EP2281047B1 (en) 2008-04-15 2020-04-08 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
JP5748223B2 (ja) * 2008-09-10 2015-07-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子およびその使用
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
BR112014010091B1 (pt) 2011-10-27 2022-11-08 Wellstat Ophthalmics Corporation Ácido nucleico, vetor viral, preparação farmacêutica, uso destes, método para produção de uma proteína rdcvf, e método in vitro ou ex vivo de secreção de uma proteína rdcvf a partir de uma célula
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
US10004780B2 (en) 2012-10-17 2018-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)
EP3027646B1 (en) 2013-07-31 2018-06-27 Novartis AG Novel selection vectors and methods of selecting eukaryotic host cells
JP6684343B2 (ja) 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
US10857240B2 (en) 2016-01-05 2020-12-08 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of ocular disorders and blinding diseases
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
BR112018076674A2 (pt) * 2016-10-11 2019-04-02 Wellstat Ophthalmics Corporation proteína de fusão entre o fator de viabilidade do cone derivado de bastonetes de forma curta e um peptídeo hidrofílico
US20230146121A1 (en) * 2019-12-09 2023-05-11 Chigenovo Co., Ltd. Use of cyp4v2 and rdcvf in the manufacture of medicament
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
EP4366757A1 (en) * 2021-07-07 2024-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathies
CN113774019B (zh) * 2021-08-11 2024-02-13 东南大学 一种脐带血间充质干细胞无血清培养基、培养方法及其应用
US20240342313A1 (en) 2023-03-30 2024-10-17 Pharma Cinq, Llc Vector encoding rod-derived cone viability factor and human igk signal sequence
US20260091133A1 (en) 2024-09-27 2026-04-02 Pharma Cinq, Llc Rod-derived cone viability factor fusion protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
GB9701710D0 (en) * 1997-01-28 1997-03-19 Karobio Ab Mammalian protein
US6106825A (en) * 1997-05-07 2000-08-22 University Of Florida Entomopoxvirus-vertebrate gene delivery vector and method
FR2784030B1 (fr) 1998-10-02 2002-12-20 Inst Nat Sante Rech Med Utilisation de bloqueurs des canaux calciques et/ou cgmp-dependants pour le traitement de pathologies de la retine
FR2784898A1 (fr) 1998-10-26 2000-04-28 Univ Pasteur Utilisation du gdnf pour le traitement de la degenerescence retinienne
EP1033405A3 (en) * 1999-02-25 2001-08-01 Ceres Incorporated Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
EP1242443A4 (en) * 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
FR2823221B1 (fr) 2001-04-06 2004-04-02 Univ Pasteur Sequences associees a la degenerescence retinienne et applications
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP5748223B2 (ja) 2008-09-10 2015-07-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子およびその使用

Similar Documents

Publication Publication Date Title
CN110172098B (zh) 抗α-突触核蛋白的单克隆抗体及其应用
CA2443345A1 (en) Disease-associated protein
CN115925928A (zh) 炎性疾病中的il-18结合蛋白(il-18bp)
UA127402C2 (uk) Моноклональне антитіло, яке специфічно зв'язується з людським pcsk9
CN102112154A (zh) IL-1α抗体及使用方法
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
US8946382B2 (en) Apelin peptides and methods of use
JP2006507231A5 (enExample)
WO2021233433A1 (zh) 抗SARS-CoV-2刺突蛋白单克隆抗体
CA2923160A1 (en) Immune system modulators
JP2007525183A5 (enExample)
CN116615221A (zh) 用于治疗细胞因子释放综合征和细胞因子风暴相关病症的靶向il-2、il-9和il-15信号传导的拮抗肽
CA2020700A1 (en) Compositions for the inhibition of protein hormone formation and uses thereof
JP2914672B2 (ja) Ｂｓｆ▲下２▼アンタゴニスト
AU8742991A (en) Antagonists of human gamma interferon
CN101891815B (zh) Ck19单克隆抗体、其制备方法及用途
JP2004537284A5 (enExample)
JP2007530420A5 (enExample)
JP2008517619A (ja) 高分子形マンノース結合型レクチンの大量生産方法
CN116419971A (zh) 抗SARS-CoV-2刺突蛋白膜外区的单克隆抗体及其应用
WO2021238854A1 (zh) 抗SARS-CoV-2刺突蛋白的单克隆抗体及其制备方法和用途
ATE398141T1 (de) Gegen den marburg i polymorphismus der faktor vii aktivierenden protease (fsap) gerichtete antikörper, ihre herstellung und verwendung
EP2364998A1 (en) Antibodies against HMGB1 and fragments thereof
JP2004533848A5 (enExample)
JP2005503113A5 (enExample)